Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
Interest Income Expense
Vertex Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Moderna Inc
NASDAQ:MRNA
|
Interest Income Expense
$345m
|
CAGR 3-Years
219%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Vertex Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
630.1m
USD
Based on the financial report for Mar 31, 2024, Vertex Pharmaceuticals Inc's Interest Income Expense amounts to 630.1m USD.
What is Vertex Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
93%
Over the last year, the Interest Income Expense growth was 328%. The average annual Interest Income Expense growth rates for Vertex Pharmaceuticals Inc have been 93% over the past three years .